Institutional Fund
Propel Bio Management, LLC
Los Angeles, CACIK 19697645 filings on record
Portfolio Value
$158.66M
Q1 2026
Holdings
38
Reported positions
New Buys
22
Opened this quarter
QoQ Change
+35.5%
from $117.12M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Plains Gp Hldgs L P19.0%
- Achieve Life Sciences Inc7.2%
- Phathom Pharmaceuticals Inc5.9%
- Delcath Sys Inc5.8%
- Corcept Therapeutics Inc3.8%
- Abeona Therapeutics Inc3.8%
- Other54.6%
Portfolio Holdings
38 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Plains Gp Hldgs L P | 1.27M | $30.18M | 19.0% | 0 | Held |
| 2 | Achieve Life Sciences Inc | 3.79M | $11.37M | 7.2% | 0 | Held |
| 3 | Phathom Pharmaceuticals Inc | 841.3K | $9.35M | 5.9% | +100.4K | Added |
| 4 | Delcath Sys Inc | 979.7K | $9.16M | 5.8% | +541.2K | Added |
| 5 | Corcept Therapeutics Inc | 147.8K | $6.02M | 3.8% | +147.8K | New |
| 6 | Abeona Therapeutics Inc | 1.33M | $6.01M | 3.8% | +499.1K | Added |
| 7 | Vor Biopharma Inc | 314.5K | $5.59M | 3.5% | +314.5K | New |
| 8 | Kyverna Therapeutics Inc | 644.4K | $5.59M | 3.5% | −22.2K | Reduced |
| 9 | Milestone Pharmaceuticals In | 4.12M | $5.08M | 3.2% | 0 | Held |
| 10 | Celldex Therapeutics Inc New | 131.4K | $4.14M | 2.6% | −22.9K | Reduced |
28 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio